Zydus Lifesciences resolves US patent dispute on bladder drug with $120 mn settlement
Under the settlement, Zydus and its US unit will also pay a pre-paid per-unit licensing fee on sales of its generic version of Mirabegron in the US from the agreement date until September 2027
Under the settlement, Zydus and its US unit will also pay a pre-paid per-unit licensing fee on sales of its generic version of Mirabegron in the US from the agreement date until September 2027
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
